GB0428328D0 - Chemical process - Google Patents

Chemical process

Info

Publication number
GB0428328D0
GB0428328D0 GBGB0428328.9A GB0428328A GB0428328D0 GB 0428328 D0 GB0428328 D0 GB 0428328D0 GB 0428328 A GB0428328 A GB 0428328A GB 0428328 D0 GB0428328 D0 GB 0428328D0
Authority
GB
United Kingdom
Prior art keywords
chemical process
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0428328.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0428328(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Priority to GBGB0428328.9A priority Critical patent/GB0428328D0/en
Publication of GB0428328D0 publication Critical patent/GB0428328D0/en
Priority to NZ555769A priority patent/NZ555769A/en
Priority to EP11162467A priority patent/EP2361906A1/en
Priority to PCT/GB2005/004999 priority patent/WO2006067456A2/en
Priority to MX2007007777A priority patent/MX2007007777A/es
Priority to CN2005800440532A priority patent/CN101084197B/zh
Priority to BRPI0518647-1A priority patent/BRPI0518647A2/pt
Priority to JP2007547647A priority patent/JP5127460B2/ja
Priority to US11/793,418 priority patent/US8034932B2/en
Priority to KR1020077017101A priority patent/KR20070092307A/ko
Priority to EP05820940A priority patent/EP1871747A2/en
Priority to CA002589775A priority patent/CA2589775A1/en
Priority to AU2005317880A priority patent/AU2005317880B2/en
Priority to IL183528A priority patent/IL183528A/en
Priority to ZA200704535A priority patent/ZA200704535B/xx
Priority to NO20072872A priority patent/NO20072872L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0428328.9A 2004-12-24 2004-12-24 Chemical process Ceased GB0428328D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB0428328.9A GB0428328D0 (en) 2004-12-24 2004-12-24 Chemical process
CA002589775A CA2589775A1 (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin
AU2005317880A AU2005317880B2 (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin
JP2007547647A JP5127460B2 (ja) 2004-12-24 2005-12-22 化学的方法
US11/793,418 US8034932B2 (en) 2004-12-24 2005-12-22 Chemical process
PCT/GB2005/004999 WO2006067456A2 (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin
MX2007007777A MX2007007777A (es) 2004-12-24 2005-12-22 Proceso para preparar rosuvastatina.
CN2005800440532A CN101084197B (zh) 2004-12-24 2005-12-22 制备罗苏伐他汀的方法
BRPI0518647-1A BRPI0518647A2 (pt) 2004-12-24 2005-12-22 processo para a produÇço de um composto, e, composto
NZ555769A NZ555769A (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin
EP11162467A EP2361906A1 (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin
KR1020077017101A KR20070092307A (ko) 2004-12-24 2005-12-22 로수바스타틴 제조 방법
EP05820940A EP1871747A2 (en) 2004-12-24 2005-12-22 Process for preparing rosuvastatin
IL183528A IL183528A (en) 2004-12-24 2007-05-29 Process for the preparation of rosvestin
ZA200704535A ZA200704535B (en) 2004-12-24 2007-05-31 Process for preparing rosuvastatin
NO20072872A NO20072872L (no) 2004-12-24 2007-06-06 Kjemisk prosess

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428328.9A GB0428328D0 (en) 2004-12-24 2004-12-24 Chemical process

Publications (1)

Publication Number Publication Date
GB0428328D0 true GB0428328D0 (en) 2005-02-02

Family

ID=34130901

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0428328.9A Ceased GB0428328D0 (en) 2004-12-24 2004-12-24 Chemical process

Country Status (15)

Country Link
US (1) US8034932B2 (https=)
EP (2) EP1871747A2 (https=)
JP (1) JP5127460B2 (https=)
KR (1) KR20070092307A (https=)
CN (1) CN101084197B (https=)
AU (1) AU2005317880B2 (https=)
BR (1) BRPI0518647A2 (https=)
CA (1) CA2589775A1 (https=)
GB (1) GB0428328D0 (https=)
IL (1) IL183528A (https=)
MX (1) MX2007007777A (https=)
NO (1) NO20072872L (https=)
NZ (1) NZ555769A (https=)
WO (1) WO2006067456A2 (https=)
ZA (1) ZA200704535B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ES2335279T3 (es) 2002-12-16 2010-03-24 Astrazeneca Uk Limited Procedimiento para la preparacion de compuestos de pirimidina.
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
KR101020024B1 (ko) 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP1948618A1 (en) * 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
EP2134696B1 (en) 2007-04-03 2017-05-17 LEK Pharmaceuticals d.d. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
EP1978020A1 (en) * 2007-04-03 2008-10-08 LEK Pharmaceuticals D.D. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
EP2178847A2 (en) * 2007-08-20 2010-04-28 Ratiopharm GmbH Process for preparing pyrimidine derivatives
EP2181089A2 (en) 2007-08-28 2010-05-05 Ratiopharm GmbH Process for preparing pentanoic diacid derivatives
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
CN105669561B (zh) * 2014-11-19 2018-11-27 南京博优康远生物医药科技有限公司 一种4-(4-氟苯基)-5-烷氧基羰基-6-异丙基-3,4-二氢嘧啶-2(1h)-酮的制备方法
MX368055B (es) * 2015-01-23 2019-09-18 Dsm Sinochem Pharm Nl Bv Procedimiento mejorado para preparar un precursor de estatina.
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480621A (en) 1892-08-09 Oiler for handsaws
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
US4625039A (en) 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4650890A (en) 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4677211A (en) 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
US5102893A (en) 1986-07-07 1992-04-07 Warner-Lambert Company Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4808621A (en) * 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4957971A (en) 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3739882A1 (de) 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
DE3741508A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Wasserloesliche disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
GB2244706B (en) 1988-02-18 1992-07-15 Bristol Myers Co Preparation of antihypercholesterolemic tetrazole intermediates
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
SG44830A1 (en) 1992-07-02 1997-12-19 Hoechst Ag Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 ５−カルボアルコキシピリミジン誘導体の合成方法
EP0790826A4 (en) 1994-11-16 1998-11-11 Synaptic Pharma Corp DIHYDROPYRIMIDINES AND THEIR USES
DE19517186A1 (de) 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
JP2000501734A (ja) 1995-12-14 2000-02-15 メルク エンド カンパニー インコーポレーテッド ジヒドロピリミジノンの製造方法
CA2296704C (en) * 1997-07-14 2010-10-19 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO1999007695A2 (en) 1997-08-05 1999-02-18 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
JP4440476B2 (ja) 1998-12-10 2010-03-24 株式会社カネカ シンバスタチンの製造方法
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
JP4204132B2 (ja) 1999-02-19 2009-01-07 大塚化学ホールディングス株式会社 摩擦材
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
EP1194582A1 (de) 1999-07-09 2002-04-10 Forschungszentrum Jülich Gmbh Verfahren zur reduktion von keto-carbonsäuren und deren estern
US6579984B1 (en) 1999-07-13 2003-06-17 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US8374574B1 (en) 2000-07-06 2013-02-12 Motorola Mobility Llc Method and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1473156A (zh) 2000-11-10 2004-02-04 - 嘧啶衍生物及其作为神经肽y受体配体的用途
MXPA03011195A (es) 2001-06-06 2004-03-18 Bristol Myers Squibb Co Proceso para preparacion de sulfonas de diol quirales e inhibidores de coa-reductasa del dihidroxiacido hmg.
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN1610657A (zh) 2001-07-06 2005-04-27 西巴特殊化学品控股有限公司 制备用于合成他汀类衍生物、特别是7－氨基3,5－二羟基庚酸衍生物的中间体的方法,及其中间体
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
CA2455842A1 (en) * 2001-08-22 2003-03-06 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE501126T1 (de) * 2002-12-10 2011-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von rosuvastatin
ES2335279T3 (es) 2002-12-16 2010-03-24 Astrazeneca Uk Limited Procedimiento para la preparacion de compuestos de pirimidina.
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
KR20060135712A (ko) 2003-12-24 2006-12-29 테바 파마슈티컬 인더스트리즈 리미티드 높은 ｓｙｎ형 대 ａｎｔｉ형 비율을 지닌 스타틴의 제조방법
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
CA2589775A1 (en) 2006-06-29
IL183528A0 (en) 2007-09-20
JP5127460B2 (ja) 2013-01-23
WO2006067456A3 (en) 2006-09-21
WO2006067456A2 (en) 2006-06-29
NO20072872L (no) 2007-09-17
AU2005317880A1 (en) 2006-06-29
BRPI0518647A2 (pt) 2008-12-02
CN101084197A (zh) 2007-12-05
MX2007007777A (es) 2007-08-14
KR20070092307A (ko) 2007-09-12
AU2005317880B2 (en) 2009-05-28
EP1871747A2 (en) 2008-01-02
CN101084197B (zh) 2012-06-13
US20080207903A1 (en) 2008-08-28
JP2008525407A (ja) 2008-07-17
ZA200704535B (en) 2008-11-26
NZ555769A (en) 2010-01-29
US8034932B2 (en) 2011-10-11
IL183528A (en) 2012-02-29
EP2361906A1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
IL208667A0 (en) Chemical process
GB0514078D0 (en) Chemical process
GB0428328D0 (en) Chemical process
GB0404793D0 (en) Process
GB0426057D0 (en) Chemical process
ZA200802416B (en) Chemical process
TWI366562B (en) Chemical process
GB0403744D0 (en) Chemical process
GB0522061D0 (en) Chemical process
GB0426059D0 (en) Chemical process
GB0427697D0 (en) Chemical process
GB0411596D0 (en) Chemical process
GB0515926D0 (en) Chemical process
GB0428103D0 (en) Chemical Process
GB0517051D0 (en) Chemical process
GB0427524D0 (en) Chemical process
GB0407521D0 (en) Chemical process
HU0400143D0 (en) Chemical process
GB0423042D0 (en) Chemical process
HU0400142D0 (en) Chemical process
GB0425449D0 (en) Chemical process
GB0419786D0 (en) Chemical process
GB0418579D0 (en) Chemical process
GB0411688D0 (en) Chemical process
GB0401540D0 (en) Process

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)